Basic information Safety Related Supplier

ChemicalBook Product Catalog API Antineoplastic agents Other antineoplastic Drugs Infliximab

1/1

Infliximab NEW

$98.00 1mg

$162.00 2mg

$273.00 5mg

Min. Order
Purity98.00%
Cas No170277-31-3
Supply Ability10g
Update time2026-04-14

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

VIP6Y

United States

United States

show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	Infliximab
CAS No	170277-31-3
EC-No
Min. Order
Purity	98.00%
Supply Ability	10g
Release date	2026/04/14

Product Introduction

Bioactivity

Name	Infliximab
Description	Infliximab is a monoclonal antibody, a human-mouse chimeric monoclonal antibody that inhibits TNF-α and prevents TNF-α from interacting with TNFR1 and TNFR2. Infliximab can be used to treat Crohn's disease and rheumatoid arthritis.
In vitro	METHODS: Human lung cancer cells A549 were pretreated with ML162 (0.1-15 µM) for 4-24 h. TXNRD1 activity was measured with the RX1 activity probe. RESULTS: RX1 signaling was significantly dose-dependently inhibited at ML162 concentrations of 0.5 µM or higher. there was also a fairly rapid onset of concentration-dependent inhibition of cellular TXNRD1 activity by ML162, and a 4 h incubation with 1 µM or higher ML162 treatment was sufficient to inhibit RX1 signaling. ML162 effectively inhibited cellular TXNRD1 activity.[1] METHODS: Melanoma cells A2058 and A375 were pretreated with ferrostatin (10 µM), Z-VAD-FMK (10 µM), or necrosulfonamide (0.5 µM) for 24 h, and cell viability was measured after ML162 (1-16 µM) treatment. RESULTS: ML162 caused cell death in a dose-dependent manner in the A2058 and A375 melanoma cell lines, which could be reversed by ferrostatin-1, a ferritin-specific inhibitor, but not by Z-VAD-FMK, an inhibitor of apoptosis, or necrosulfonamide, an inhibitor of necroptosis. [2]
In vivo	METHODS: To detect anti-tumor activity in vivo, ML162 (40 mg/kg once daily) and anti-PD-1 antibody (200 µg every three days) were intraperitoneally injected into BALB/c mice bearing TS/A tumors once daily for two weeks. RESULTS: The combination of GPX4 inhibitor and anti-PD-1 antibody significantly inhibited tumor growth compared to monotherapy. The combination therapy did not result in additional immune cell infiltration compared to monotherapy, but the combination therapy induced a significant immune response with an increased proportion of PRF1+CD8+ T cells and GZMB+CD8+ T cells. [3]
Storage	Shipping with blue ice/Shipping at ambient temperature.
Keywords	Tumor Necrosis Factor Receptor \| TNFR2 \| TNFR1 \| TNFR \| TNF Receptor \| PTP1B \| neuropathy \| monoclonal \| Inhibitor \| inhibit \| Infliximab \| diabetic \| CT-P13 \| Avakine \| autoimmune \| anti-inflammatory
Inhibitors Related	Neomycin sulfate \| Adipic dihydrazide \| Levulinic acid \| D(+)-Raffinose pentahydrate \| Sulfamethoxazole sodium \| Terbinafine hydrochloride \| Doxycycline \| Hyaluronic acid sodium (MW 20 kDa) \| Dimethyl sulfoxide \| Sodium diacetate \| Sodium bicarbonate \| BES

show more

Company Profile Introduction

You may like

Recommended supplier

Send Inquriy